Valeriy Domenyuk

Valeriy Domenyuk

Auto-generated profile, based on publicly available information

Valeriy Domenyuk

Caris Life Sciences, Irving, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
DMDaniel Magee
Daniel Magee
VDValeriy Domenyuk
Valeriy Domenyuk
JAJim Abraham
Jim Abraham
NBNieves Perdigones Borderias
Nieves Perdigones Borderias
JSJeff Swensen
Jeff Swensen
DSDavid Spetzler
David Spetzler
Purpose: Plasma-based liquid biopsy tests can detect tumor-specific genetic alterations and offer many advantages that complement tissue-based comprehensive genomic profiling. However, age-related clonal hematopoiesis (CH) mutations can confound liquid biopsy results and potentially lead to incorrect therapy choice. Experimental Design: We assessed the landscape of 16,812 liquid profiles across 49 cancer types using the Caris Assure assay, a whole-exome and whole-transcriptome next-generation sequencing workflow that independently sequences both plasma-derived cell-free total nucleic acids and the white blood cell DNA and RNA from the buffy coat. The variant source was identified algorithmically by comparing plasma and buffy coat variant frequency and read quality metrics. Results: Of 16,812 patients, 42.3% presented at least one CH variant among reportable clinical genes. We found 39% of BRCA2 variants to be of CH origin, as well as 37.9% of CHEK2, 27.4% of BRCA1, 20.1% of ATM, 7.3% of NRAS, 5.8% of BRAF, 2.1% of EGFR, 2.1% of KRAS, and 18.5% of TP53. For patients aged 65 to 69 years, the median proportion of CH variant classification was 20%, whereas it was 33% for patients aged 70 to 74 years, 33% for ages 75 to 79 years, and 50% for ages 80+ years. We found high rates of CH detected in what would be otherwise druggable targets in many cancer types typically treated with PARP inhibitors, including breast, female genital tract, ovarian, pancreatic, prostate, and endometrial cancers. Conclusions: This large study highlights the need for thorough CH classification during liquid biopsy to appropriately recommend therapies, especially PARP inhibitors. See related commentary by Bernard and Micol, p. 2545

1 July 2025
Verified
Other
Open access
DMDaniel Magee
Daniel Magee
VDValeriy Domenyuk
Valeriy Domenyuk
JAJim Abraham
Jim Abraham
NBNieves Perdigones Borderias
Nieves Perdigones Borderias
JSJeff Swensen
Jeff Swensen
DSDavid Spetzler
David Spetzler
Supplemental Table 2 shows the complete list of variants detected and their source (tumor, germline, CH) in the liquid biopsy cohort.

1 July 2025
Verified
Other
Open access
DMDaniel Magee
Daniel Magee
VDValeriy Domenyuk
Valeriy Domenyuk
JAJim Abraham
Jim Abraham
NBNieves Perdigones Borderias
Nieves Perdigones Borderias
JSJeff Swensen
Jeff Swensen
DSDavid Spetzler
David Spetzler
Supplemental Table 1 shows specimens by cancer type; Supplemental Figure 1 shows CH variants by patient age; Supplemental Figure 2 shows variant classification by gDNA and plasma variant frequency for gDNA VF ≤ 0.20